Obesity in psoriasis: The metabolic, clinical and therapeutic implications. Report of an interdisciplinary conference and review

British Journal of Dermatology

Volumn 157, Issue 4, 2007, Pages 649-655

  Sterry, W ^a   Strober, B E ^b   Menter, A ^c  

^a CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^b NEW YORK UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

Author keywords

Metabolic syndrome; Myocardial infarction; Obesity; Psoriasis; Psoriatic arthritis

Indexed keywords

CYTOKINE;

ABDOMINAL OBESITY; ADIPOSE TISSUE; CARDIOVASCULAR RISK; CLINICAL FEATURE; COMORBIDITY; CONFERENCE PAPER; DISEASE ASSOCIATION; DISEASE SEVERITY; DYSLIPIDEMIA; EVIDENCE BASED MEDICINE; HEALTH HAZARD; HEART INFARCTION; HUMAN; HYPERTENSION; INFLAMMATION; INSULIN RESISTANCE; MEDICAL EXPERT; MEDICAL LITERATURE; METABOLIC SYNDROME X; NONALCOHOLIC FATTY LIVER; PATIENT CARE; PREVALENCE; PRIORITY JOURNAL; PSORIASIS; RHEUMATOID ARTHRITIS;

EID: 34548588714     PISSN: 00070963     EISSN: 13652133     Source Type: Journal    
DOI: 10.1111/j.1365-2133.2007.08068.x     Document Type: Conference Paper

References (56)

1. Hossain P, Kawar B, el-Nahas M. Obesity and diabetes in the developing world - a growing challenge. N Engl J Med 2007 356 : 213 15.
2. Shirai K. Obesity as the core of the metabolic syndrome and the management of coronary heart disease. Curr Med Res Opin 2004 20 : 295 304.
3. Henseler T, Christophers E. Disease concomitance in psoriasis. J Am Acad Dermatol 1995 32 : 982 6.
4. Krueger G, Papp K, Stough D et al. A randomized, double-blind, placebo-controlled phase III study evaluating efficacy and tolerability of 2 courses of alefacept in patients with chronic plaque psoriasis. J Am Acad Dermatol 2002 47 : 821 33.
5. Mease P, Goffe B, Metz J et al. Etanercept in the treatment of psoriatic arthritis and psoriasis: a randomized trial. Lancet 2000 356 : 385 90.
6. Naldi L, Chatenoud L, Linder D et al. Cigarette smoking, body mass index, and stressful life events as risk factors for psoriasis: results from an Italian case-control study. J Invest Dermatol 2005 125 : 61 7.
7. Neimann A, Shin D, Wang X et al. Prevalence of cardiovascular risk factors in patients with psoriasis. J Am Acad Dermatol 2006 55 : 829 35.
8. Herron M, Hinckley B, Hoffman M et al. Impact of obesity and smoking on psoriasis presentation and management. Arch Dermatol 2005 141 : 1527 34.
9. National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III): final report. Circulation 2002 106 : 3143 421.
10. Eckel R, Grundy S, Zimmet P. The metabolic syndrome. Lancet 2005 365 : 1415 28.
11. Gelfand J, Neimann A, Shin D et al. Risk of myocardial infarction in patients with psoriasis. JAMA 2006 296 : 1735 41.
12. Rocha-Pereira P, Santos-Silva A, Rebelo I et al. Dislipidemia and oxidative stress in mild and in severe psoriasis as a risk for cardiovascular disease. Clin Chim Acta 2001 303 : 33 9.
13. Sommer D, Jenisch S, Suchan M et al. Increased prevalence of the metabolic syndrome in patients with moderate to severe psoriasis. Arch Dermatol Res 2006 298 : 321 8.
14. Sattar N, McCarey D, Capell H, McInnes I. Explaining how 'high-grade' systemic inflammation accelerates vascular risk in rheumatoid arthritis. Circulation 2003 108 : 2957 63.
15. Ronti T, Lupattelli G, Mannarino E. The endocrine function of adipose tissue: an update. Clin Endocrinol 2006 64 : 355 65.
16. Pischon T, Girman C, Hotamisligil G et al. Plasma adiponectin levels and risk of myocardial infarction in men. JAMA 2004 291 : 1730 7.
17. Bonifati C, Carducci M, Cordiali Fei P et al. Correlated increases of tumour necrosis factor-α, interleukin-6 and granulocyte monocyte-colony stimulating factor levels in suction blister fluids and sera of psoriatic patients - relationships with disease severity. Clin Exp Dermatol 1994 19 : 383 7.
18. Krueger JG. The immunologic basis for the treatment of psoriasis with the new biologic agents. J Am Acad Dermatol 2002 46 : 1 23.
19. Nickoloff B, Karabin G, Barker J et al. Cellular localization of interleukin-8 and its inducer, tumor necrosis factor-alpha in psoriasis. Am J Pathol 1991 138 : 129 40.
20. Coppack S. Pro-inflammatory cytokines and adipose tissue. Proc Nutr Soc 2001 60 : 349 56.
21. Pietsch J, Batra A, Stroh T et al. Toll-like receptor expression and response to specific stimulation in adipocytes and preadipocytes. Ann NY Acad Sci 2006 1072 : 407 9.
22. Rajala M, Scherer P. Minireview: the adipocyte - at the crossroads of energy homeostasis, inflammation and atherosclerosis. Endocrinology 2003 144 : 3765 73.
23. Clark J. The epidemiology of nonalcoholic fatty liver disease in adults. J Clin Gastroenterol 2006 40 : S5 10.
24. Lonardo A, Loria P, Carulli N. Concurrent non-alcoholic steatohepatitis and psoriasis. Report of three cases from the POLI.ST.E.N.A. study. Dig Liver Dis 2001 33 : 86 7.
25. Matsumoto T, Suzuki N, Watanabe H et al. Nonalcoholic steatohepatitis associated with psoriasis vulgaris. J Gastroenterol 2004 39 : 1102 5.
26. Langman G, Hall PM, Todd G. Role of non-alcoholic steatohepatitis in methotrexate-induced liver injury. J Gastroenterol Hepatol 2001 16 : 1395 401.
27. Kremer J, Alarcón G, Lightfoot RJ et al. Methotrexate for rheumatoid arthritis: suggested guidelines for monitoring liver toxicity. Arthritis Rheum 1994 37 : 316 28.
28. Whiting-O'Keefe Q, Fye K, Sack K. Methotrexate and histologic hepatic abnormalities: a meta-analysis. Am J Med 1991 90 : 711 16.
29. Roenigk HJ, Auerbach R, Maibach H et al. Methotrexate in psoriasis: consensus conference. J Am Acad Dermatol 1998 38 : 478 85.
30. Villanova N, Moscatiello S, Ramilli S et al. Endothelial dysfunction and cardiovascular risk profile in nonalcoholic fatty liver disease. Hepatology 2005 42 : 270 2.
31. del Rincon I, Williams K, Stern M et al. High incidence of cardiovascular events in a rheumatoid arthritis cohort not explained by traditional cardiac risk factors. Arthritis Rheum 2001 44 : 2737 45.
32. Goodson N, Wiles N, Lunt M et al. Mortality in early inflammatory polyarthritis: cardiovascular mortality is increased in seropositive patients. Arthritis Rheum 2002 46 : 2010 19.
33. Solomon D, Karlson E, Rimm E et al. Cardiovascular morbidity and mortality in women diagnosed with rheumatoid arthritis. Circulation 2003 107 : 1303 7.
34. Wallberg-Jonsson S, Ohman M, Dahlqvist S. Cardiovascular morbidity and mortality in patients with seropositive rheumatoid arthritis in Northern Sweden. J Rheumatol 1997 24 : 445 51.
35. Hill J, Zalos G, Halcox J et al. Circulating endothelial progenitor cells, vascular function, and cardiovascular risk. N Engl J Med 2003 348 : 593 600.
36. Werner N, Kosiol S, Schiegl T et al. Circulating endothelial progenitor cells and cardiovascular outcomes. N Engl J Med 2005 353 : 999 1017.
37. Grisar J, Aletaha D, Steiner C et al. Depletion of endothelial progenitor cells in the peripheral blood of patients with rheumatoid arthritis. Circulation 2005 111 : 204 11.
38. Mallbris L, Akre O, Granath F et al. Increased risk for cardiovascular mortality in psoriasis inpatients but not in outpatients. Eur J Epidemiol 2004 19 : 225 30.
39. McDonald C, Calabresi P. Psoriasis and occlusive vascular disease. Br J Dermatol 1978 99 : 469 75.
40. Poikolainen K, Karvonen J, Pukkala E. Excess mortality related to alcohol and smoking among hospital-treated patients with psoriasis. Arch Dermatol 1999 135 : 1490 3.
41. Kural B, Örem A, Çimşit G et al. Evaluation of the atherogenic tendency of lipids and lipoprotein content and their relationships with oxidant-antioxidant system in patients with psoriasis. Clin Chim Acta 2003 328 : 71 82.
42. Reynoso-von Drateln C, Martinez-Abundis E, Balcazar-Munoz B et al. Lipid profile, insulin secretion, and insulin sensitivity in psoriasis. J Am Acad Dermatol 2003 48 : 882 5.
43. Ludwig R, Herzog C, Rostock A et al. Psoriasis: a possible risk factor for development of coronary artery calcification. Br J Dermatol 2007 156 : 271 6.
44. Escalante A, Haas R, del Rincon I. Paradoxical effect of body mass index on survival in rheumatoid arthritis: role of comorbidity and systemic inflammation. Arch Intern Med 2005 165 : 1624 9.
45. Dominguez H, Storgaard H, Rask-Madsen C et al. Metabolic and vascular effects of tumor necrosis factor-α blockade with etanercept in obese patients with type 2 diabetes. J Vasc Res 2005 42 : 517 25.
46. Bernstein L, Berry J, Kim S et al. Effects of etanercept in patients with the metabolic syndrome. Arch Intern Med 2006 166 : 902 8.
47. Gonzalez-Juanatey C, Llorca J, Sanchez-Andrade A et al. Short-term adalimumab therapy improves endothelial function in patients with rheumatoid arthritis refractory to infliximab. Clin Exp Rheumatol 2006 24 : 309 12.
48. Hürlimann D, Forster A, Noll G et al. Anti-tumor necrosis factor-α treatment improves endothelial function in patients with rheumatoid arthritis. Circulation 2002 106 : 2184 7.
49. Gonzalez-Gay M, De Matias J, Gonzalez-Juanatey C et al. Anti-tumor necrosis factor-α blockade improves insulin resistance in patients with rheumatoid arthritis. Clin Exp Rheumatol 2006 24 : 83 6.
50. Dahlqvist S, Engstrand S, Berglin E, Johnson O. Conversion towards an atherogenic lipid profile in rheumatoid arthritis patients during long-term infliximab therapy. Scand J Rheumatol 2006 35 : 107 11.
51. Popa C, Netea M, Radstake T et al. Influence of anti-tumour necrosis factor therapy on cardiovascular risk factors in patients with active rheumatoid arthritis. Ann Rheum Dis 2004 64 : 303 5.
52. Vis M, Nurmohamed M, Wolbink G et al. Short term effects of infliximab on the lipid profile in patients with rheumatoid arthritis. J Rheumatol 2005 32 : 252 5.
53. Prodanovich S, Ma F, Taylor JR et al. Methotrexate reduces incidence of vascular diseases in veterans with psoriasis or rheumatoid arthritis. J Am Acad Dermatol 2005 52 : 262 7.
54. Choi H, Hernan M, Seeger J et al. Methotrexate and mortality in patients with rheumatoid arthritis: a prospective study. Lancet 2002 359 : 1173 9.
55. Jacobsson L, Turesson C, Gulfe A et al. Treatment with tumor necrosis factor blockers is associated with a lower incidence of first cardiovascular events in patients with rheumatoid arthritis. J Rheumatol 2005 32 : 1213 18.
56. Mease P, Menter M. Quality-of-life issues in psoriasis and psoriatic arthritis: outcome measures and therapies from a dermatological perspective. J Am Acad Dermatol 2006 54 : 685 704.